Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia

Raffaele Palmieri,[1,2] Megan Othus,[3] Guang-Shing Cheng,[2,4]
Francesco Buccisano,[1] Giovangiacinto Paterno,[1] Luca Maurillo,[1] Maria Ilaria Del Principe,[1] Giuseppe Sconocchia,[5] Adriano Venditti,[1] and Roland B. Walter[2,6,7,8]

[1]Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy; [2]Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; [3]Public Health Science Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; [4]Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA, USA; [5]Institute of Translational Pharmacology, Department of Biomedical Sciences, CNR, Rome, Italy; [6]Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; [7]Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA and [8]Department of Epidemiology, University of Washington, Seattle, WA, USA

Correspondence:
ROLAND B. WALTER - rwalter@fredhutch.org

TABLE 1S. Characteristics of 196 patients who had no pulmonary symptoms and lacked Ferrara unfitness-defining pulmonary comorbidities.

	Number (%) [Total=196]
Female gender	83 (42%)
Smoking history	74 (38%)
Pulmonary function testing	
*Normal**	38 (19%)
*Mildly abnormal***	65 (33%)
*Moderately abnormal****	81 (41%)
*Severely abnormal*****	12 (6%)
Chest imaging	
Normal	114 (58%)
Stable	26 (13%)
New	31 (16%)
Increased	1 (<1%)
Decreased	21 (11%)
Documented lung disease$	8 (4%)
Ferrara score pulmonary	
Fit	184 (94%)
Unfit	12 (6%)

*DLCO and FEV1 ≥91%; **DLCO and/or FEV1 81-90%; ***DLCO and/or FEV1 66-80%; ****DLCO and/or FEV1 ≤65%

$Comorbidities not qualifying for Ferrara unfitness per se.

Pulmonary Ferrara criteria denoting patient to be "unfit": DLCO and/or FEV1 ≤65%, dyspnea at rest, need for supplemental oxygen, or history of any pleural neoplasm or uncontrolled lung neoplasm.

FIGURE 1S. Study cohort distribution according to PFTs status, pulmonary comorbidities and chest imaging findings.